Cas no 72432-10-1 (Aniracetam)
Aniracetam Chemical and Physical Properties
Names and Identifiers
-
- aniracetam
- 1-(4-methoxybenzoyl)-2-pyrrolidinone
- 1-(4-methoxybenzoyl)pyrrolidin-2-one
- Ro 13-5057
- 1-anisoyl-2-pyrrolidinone
- 1-p-Anisoyl-2-pyrrolidinone
- Ampamet
- Draganon
- p-Methoxybenzoyl-2-pirrolidone
- Sarpul
- 1-(4-Methoxybenzoyl)-2-pyrrolidone
- Aniracetamun [INN-Latin]
- Aniracetam [USAN:INN:JAN]
- Ro 135057
- 1-p-anisoylpyrrolidin-2-one
- 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-
- MLS000079240
- 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N
- 5L16LKN964
- SMR000038438
- 1-[(4-metho
- NCGC00015116-05
- SR-01000003147-2
- EU-0100115
- BCP9000303
- ANIRACETAM [WHO-DD]
- SBI-0050103.P004
- IDI1_000403
- DB04599
- SPECTRUM1503078
- NSC-758223
- NCGC00015116-10
- ANIRACETAM [JAN]
- aniracetam;p-methoxybenzoyl-2-pirrolidone
- ANIRACETAM [MI]
- A 9950
- HMS3657G11
- AKOS005066313
- NS00017748
- AB04115
- NCGC00015116-08
- NCGC00015116-04
- NCGC00021402-06
- CHEMBL36994
- ANIRACETAM; 1-P-ANISOYL-2-PYRROLIDINONE
- BRD-K88611939-001-02-6
- Aniracetam, >=98%
- KBio2_004390
- HMS2094K07
- NCGC00015116-07
- KBioSS_001822
- NCGC00021402-05
- CHEBI:47943
- Ro-13-5057
- BA164183
- BPBio1_001316
- NCGC00021402-07
- MFCD00153767
- NCGC00021402-02
- SCHEMBL70998
- NCGC00015116-01
- HMS3266L08
- HMS501E05
- 1-(p-methoxybenzoyl)-2-pyrrolidinone
- LP00115
- BRD-K88611939-001-13-3
- DivK1c_000403
- HMS3260G12
- HMS2234E11
- Spectrum5_001609
- Aniracetamun
- Lopac-A-9950
- H10883
- Reset
- Aniracetam ,(S)
- Aniracetam (JAN/USAN/INN)
- Opera_ID_294
- NCGC00015116-06
- DTXSID5045128
- Spectrum_001342
- HY-10932
- ANIRACETAM [INN]
- NCGC00021402-08
- Tox21_110086
- SR-01000003147-8
- 72432-10-1
- MLS000028591
- Spectrum4_000761
- HMS3411P17
- NCGC00015116-11
- CAS-72432-10-1
- HMS3713N20
- CS-1793
- NCGC00260800-01
- Biomol-NT_000222
- Pharmakon1600-01503078
- 1-(p-Methoxybenzoyl)-2-pyrrolidinon
- KS-5313
- NSC 758223
- HMS2089O17
- SDCCGSBI-0050103.P005
- Q417630
- NCGC00015116-13
- HMS3884C09
- GTPL4133
- KBio2_006958
- MLS001201800
- 1-[(4-methoxyphenyl)carbonyl]pyrrolidin-2-one
- KBio1_000403
- BRN 4807205
- Tocris-0867
- UNII-5L16LKN964
- Tox21_500115
- DTXCID3025128
- ANIRACETAM [MART.]
- SY052612
- 1-(4-Methoxybenzoyl)-2-pyrrolidinone #
- SR-01000003147
- CCG-204210
- NCGC00015116-12
- NCGC00015116-03
- BSPBio_003026
- BCPP000399
- NCGC00015116-02
- HMS3675P17
- Ro-135057
- Ro-13-3057
- KBio2_001822
- s1281
- Tox21_110086_1
- KBio3_002526
- SR-01000003147-4
- Lopac0_000115
- SR-01000003147-6
- AB00053303_15
- Spectrum3_001553
- HB0116
- NCGC00015116-09
- D01883
- NCGC00015116-24
- AC-15651
- A837527
- AB00053303_16
- ANIRACETAM [USAN]
- KBioGR_001142
- NSC758223
- BCP02091
- SW199095-2
- AB00053303-14
- Memodrin
- 1-(4-Methoxy-benzoyl)-pyrrolidin-2-one
- FT-0649064
- NINDS_000403
- BRD-K88611939-001-23-2
- BRD-K88611939-001-22-4
- A2394
- Aniracetam
-
- MDL： MFCD00153767
- Inchi： 1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
- InChI Key： ZXNRTKGTQJPIJK-UHFFFAOYSA-N
- SMILES： O=C1CCCN1C(C1C=CC(=CC=1)OC)=O
- BRN： 4807205
Computed Properties
- Exact Mass: 219.09000
- Monoisotopic Mass: 219.08954328g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 16
- Rotatable Bond Count: 2
- Complexity: 282
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 2
- XLogP3: 1.6
- Topological Polar Surface Area: 46.6
Experimental Properties
- Color/Form: White crystalline solid.
- Density: 1.236
- Melting Point: 120.0 to 124.0 deg-C
- Boiling Point: 399.7±34.0°C at 760 mmHg
- Flash Point: 195.5±25.7 °C
- Refractive Index: 1.573
- Solubility: In vitro: DMSO solubility ≥ 100 mg/ml (456.12 mm) H2O: 0.33 mg/ml (1.51 mm; need ultrasonic) * "≥" means soluble, but saturation unknown
- Water Partition Coefficient: Soluble in chloroform. Also soluble in ethanol. Insoluble in water
- PSA: 46.61000
- LogP: 1.39570
- Merck: 662
- Solubility: Not determined
Aniracetam Security Information
- Prompt：warning
- Signal Word：Warning
- Hazard Statement： H303
- Warning Statement： P312
- WGK Germany：2
- Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- RTECS：UY5781900
- Toxicity：LD50 in rats, mice (mg/kg): ~4500, >5000 orally (Cumin)
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Aniracetam Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-10932-10mM*1mLinDMSO |
Aniracetam |
72432-10-1 | 99.95% | 10mM*1mLinDMSO |
￥550 | 2022-05-18 | |
| MedChemExpress | HY-10932-500mg |
Aniracetam |
72432-10-1 | 99.94% | 500mg |
￥500 | 2025-04-16 | |
| MedChemExpress | HY-10932-1g |
Aniracetam |
72432-10-1 | 99.94% | 1g |
￥720 | 2025-04-16 | |
| MedChemExpress | HY-10932-5g |
Aniracetam |
72432-10-1 | 99.94% | 5g |
￥2470 | 2025-04-16 | |
| S e l l e c k ZHONG GUO | S1281-50mg |
Aniracetam |
72432-10-1 | 99.93% | 50mg |
￥576.08 | 2023-09-16 | |
| S e l l e c k ZHONG GUO | S1281-200mg |
Aniracetam |
72432-10-1 | 99.93% | 200mg |
￥1406.05 | 2023-09-16 | |
| S e l l e c k ZHONG GUO | S1281-250mg |
Aniracetam |
72432-10-1 | 99.93% | 250mg |
￥1556.1 | 2023-09-16 | |
| DC Chemicals | DC8976-1 g |
Aniracetam |
72432-10-1 | >98% | 1g |
$300.0 | 2022-03-01 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD114391-250mg |
1-(4-Methoxybenzoyl)pyrrolidin-2-one |
72432-10-1 | 97% | 250mg |
￥57.0 | 2024-04-18 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD114391-1g |
1-(4-Methoxybenzoyl)pyrrolidin-2-one |
72432-10-1 | 97% | 1g |
￥132.0 | 2024-04-18 |
Aniracetam Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Aniracetam Related Literature
-
Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
-
Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
-
Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
-
Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
Additional information on Aniracetam
Professional Introduction to Aniracetam (CAS No. 72432-10-1)
Aniracetam, a derivative of racetam, is a cognitive enhancer that has garnered significant attention in the field of neuropharmacology and psychopharmacology. With the CAS number 72432-10-1, this compound is widely recognized for its potential nootropic effects, which include improved memory, enhanced learning capabilities, and increased mental clarity. Over the years, extensive research has been conducted to elucidate its mechanism of action and explore its therapeutic applications.
The pharmacological profile of Aniracetam is characterized by its high lipophilicity, which allows it to cross the blood-brain barrier efficiently. This property is crucial for its efficacy as a cognitive enhancer, as it ensures that the compound reaches the central nervous system in sufficient concentrations. Early studies demonstrated that Aniracetam could significantly improve cognitive functions in both healthy individuals and those with cognitive impairments.
Recent advancements in neuroscientific research have further highlighted the potential of Aniracetam in treating various neurological and psychiatric disorders. For instance, studies have shown that it may have neuroprotective properties, making it a candidate for the management of Alzheimer's disease and other dementias. The compound's ability to modulate cholinergic systems and enhance acetylcholine levels in the brain has been particularly noteworthy.
In addition to its cognitive-enhancing effects, Aniracetam has also been investigated for its anxiolytic and mood-stabilizing properties. Research indicates that it may help reduce anxiety and improve mood by interacting with serotonin receptors in the brain. These findings have opened up new avenues for exploring its use in treating conditions such as generalized anxiety disorder and depression.
The synthesis and structural chemistry of Aniracetam (CAS No. 72432-10-1) have been thoroughly studied to optimize its pharmacokinetic and pharmacodynamic properties. The compound's molecular structure, featuring a pyrrolidone ring and an amine group, contributes to its unique pharmacological profile. Researchers have explored various synthetic routes to produce Aniracetam with high purity and yield, ensuring that it meets the stringent standards required for clinical use.
One of the most compelling aspects of Aniracetam research is its potential role in enhancing cognitive functions without the sedative effects commonly associated with other nootropics. This makes it an attractive option for individuals seeking to improve mental performance without compromising alertness or daytime energy levels. Clinical trials have shown that Aniracetam can significantly improve working memory, attention span, and information processing speed.
The therapeutic applications of Aniracetam extend beyond cognitive enhancement. Preliminary studies have suggested that it may have neuroprotective effects against oxidative stress and excitotoxicity, which are key mechanisms involved in neuronal damage. This has led to investigations into its potential use in preventing or mitigating neurodegenerative diseases such as Parkinson's disease and Huntington's disease.
The safety profile of Aniracetam has been extensively evaluated through preclinical and clinical studies. Generally, it is well-tolerated when used at recommended doses, with common side effects including mild gastrointestinal discomfort and headaches. However, long-term studies are still needed to fully understand its safety implications and potential interactions with other medications.
Future research directions for Aniracetam (CAS No. 72432-10-1) include exploring its mechanisms of action at a molecular level and identifying new therapeutic targets. Advances in techniques such as positron emission tomography (PET) imaging are enabling researchers to visualize how Aniracetam affects brain activity in real-time. These insights could lead to more refined applications of the compound in treating neurological and psychiatric disorders.
The growing interest in natural cognitive enhancers has also spurred investigations into synthetic derivatives of Aniracetam that may offer improved efficacy or reduced side effects. By modifying its chemical structure, researchers aim to develop compounds that retain the beneficial cognitive effects while minimizing potential adverse reactions.
In conclusion, Aniracetam represents a significant advancement in the field of nootropics due to its potent cognitive-enhancing properties and broad therapeutic potential. Its unique pharmacological profile, combined with ongoing research efforts, positions it as a promising candidate for treating various neurological and psychiatric conditions. As our understanding of its mechanisms of action continues to evolve, so too will its applications in enhancing human cognitive function.
72432-10-1 (Aniracetam) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
